Preliminary studies in rodents with NAFLD show a marked reduction in steatosis and hepatic inflammation: For example, Yaq-001, a synthetic activated carbon with the ability to selectively absorb intestinal-derived toxins (such as cytokines, hydrophobic bile acid and bacterial products) produced a significant reduction in ALT and hepatic TLR-4 expression in rodents with NAFLD [174]. The gene discussed is TLR4; the disease is metabolic dysfunction-associated steatotic liver disease.